Suspension of ODE activities
This article was originally published in The Gray Sheet
Executive SummaryFDA plans to announce in an upcoming Federal Register notice a two- to three-week suspension of the Office of Device Evaluation's activities, along with a suspension of the office's statutory review clock, to allow for relocation of ODE offices. The move from 1390 Piccard Drive to 9200 Corporate Blvd. in Gaithersburg, Maryland is expected to take place in October ("The Gray Sheet" Aug. 15, In Brief). The notice will be similar to one that was published in 1989 when it moved from Silver Spring, Maryland to its current location ("The Gray Sheet" May 29, 1989, In Brief)
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.
At the OurCrowd Global Investor Summit, in Jerusalem, Israel, on 13 February, Medtech Insight met with start-up Sweetch, which has developed a personalized digital health coach for wellness and disease management.